At Acceleron, we are dedicated to bringing innovative, life-changing therapies to patients with a wide range of serious and rare diseases. Our scientific leadership and broad platform have enabled us to produce a rich pipeline of important new medicines for pulmonary diseases and rare blood disorders.

  • In our pulmonary program, we are developing sotatercept for the treatment of pulmonary arterial hypertension, having recently reported positive topline results from the Phase 2 PULSAR trial and actively enrolling patients in the Phase 2 SPECTRA trial. We are currently conducting multiple Phase 3 trials with the potential to support a long-term vision of establishing sotatercept as a backbone therapy for patients with PAH in all stages of the disease. The main registrational Phase 3 trial, known as STELLAR, is now open for enrollment.
  • Luspatercept is a first-in-class erythroid (red blood cell) maturation agent being developed to treat patients who have anemia-associated with serious blood disorders. Discovered by scientists at Acceleron, luspatercept-aamt is a recombinant fusion protein that binds several TGF-beta superfamily ligands, thereby diminishing Smad2/3 signaling. The U.S. Food and Drug Administration has approved REBLOZYL® (luspatercept-aamt) for the treatment of anemia associated with certain rare blood disorders. Bristol Myers Squibb is developing luspatercept for the treatment on anemia in patient populations of myelodysplastic syndromes, beta-thalassemia, and myelofibrosis.

The clinical trials listed below are Acceleron or partner-sponsored trials, some of which are actively recruiting patients. Each trial in the list contains a link to clinicaltrials.gov, where you will find a full description and contact information.

Clinical Trial Transparency: Acceleron is committed to public health and scientific exchange. As a part of this commitment, we make our clinical trial information accessible so that patients, healthcare providers, and the general public are included in the conversation. Click here to learn more about Acceleron’s Policy on Clinical Trial Transparency.

Now enrolling: COMMANDS
A Phase 3 trial for patients with low or intermediate-risk MDS. Learn More.